erlotinib hydrochloride has been researched along with ezetimibe in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 2,484 | 563 | 1,465 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | ezetimibe (IC50) |
|---|---|---|---|
| NPC1-like intracellular cholesterol transporter 1 | Homo sapiens (human) | 0.37 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sundermeyer, M; Veeraputhiran, M | 1 |
1 other study(ies) available for erlotinib hydrochloride and ezetimibe
| Article | Year |
|---|---|
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |